INFORLIFE
GenericsINFORLIFE is a generic drug manufacturer focused on Cardiovascular, Infectious Disease. Key products include MIDAZOLAM IN 0.9% SODIUM CHLORIDE.
INFORLIFE's Key Drugs
INFORLIFE's core commercial portfolio centers on NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE, MIDAZOLAM IN 0.9% SODIUM CHLORIDE, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Angina
Angina
Anxiety
Hypotension
INFORLIFE's Recent FDA Approvals
New NDA/BLA approvals for INFORLIFE over the last two years — novel drugs only, excluding generics and label supplements.
INFORLIFE's Therapeutic Areas
INFORLIFE's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
INFORLIFE's Top Competitors
INFORLIFE's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
INFORLIFE Pipeline Snapshot
Active clinical trials for INFORLIFE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (0)
Company Info
- First Approval
- 2008-03-18
- Latest
- 2025-08-15
- Applications
- 11